Revenue of breast and prostate cancer diagnostics in Europe totaled US$ 3,949.1 million in 2022 and is expected to reach US$ 4,041.5 million by 2023. Over the assessment period, demand for breast and prostate cancer diagnostics across Europe is set to rise at 2.2% CAGR. By 2033, the total revenue in Europe is expected to reach US$ 5,030.1 million.
Revenue in Europe to Expand Around 1.3X through 2033
Breast and prostate cancer diagnostics revenue in Europe is expected to expand by about 1.3X by 2033. This is attributable to the rising prevalence of breast and prostate cancer, the growing needs for early cancer detection, favorable government support, and advancements in cancer diagnostics technology.
Europe is witnessing a dramatic rise in the cases of breast and prostate cancer. This is creating a surging demand for cancer diagnostic testing in countries across Europe, thereby fostering growth.
Government initiatives and screening programs are anticipated to play key roles in boosting revenue across Europe. Several countries in Europe are launching breast screening programs, which are expected to drive demand in the region.
For instance, the new European Cancer Imaging Initiative was launched in December 2022. Such initiatives will present lucrative opportunities for breast and prostate cancer diagnostics companies.
Other trends in breast and prostate cancer diagnosis space in Europe
Biopsy and Liquid Biopsy Segments to Collectively Hold 43% Share
As per the latest Europe breast and prostate cancer diagnostics industry analysis, the biopsy and liquid biopsies segment is expected to hold around 43% share through 2033 collectively. This is due to the rising patient preference for biopsies and liquid biopsies due to their high effectiveness and reliable nature.
Biopsies and liquid biopsies are becoming suitable tools for diagnosing breast and prostate cancer. They are the ideal means to diagnose these cancer types definitively. As a result, medical professionals often recommend these cancer diagnostic tests to patients for early cancer detection.
Advancements in biopsy procedures, such as MRI-targeted biopsies, 3D optical biopsies, and ultrasound-guided biopsies, are anticipated to boost the target segments further. As a result, a dominant share has been predicted for biopsy and liquid biopsy segments.
Research and Development Activities Becoming Key Focus of Companies
The rising burden of cancer is triggering innovation in diagnostic and treatment approaches. Both governments and critical companies are spending rigorously in research & development activities to advance cancer diagnostics and develop new and more effective cancer diagnostics tests.
Ongoing research in breast cancer diagnostics, including developing new biomarkers and genetic testing methods, is set to facilitate growth in Europe. Similarly, the introduction and popularity of targeted therapies & personalized diagnostics approaches will bode well for this business.
Companies are also exploring new imaging techniques, such as digital breast tomosynthesis (DBT), that detect smaller and earlier-stage tumors than conventional mammograms. This is expected to strengthen their regional presence and boost their revenue.
Industry Outlook
| Attributes | Key Insights |
|---|---|
| Base Value (2022) | US$ 3,949.1 million |
| Estimated Value (2023) | US$ 4,041.5 million |
| Projected Value (2033) | US$ 5,030.1 million |
| CAGR (2023 to 2033) | 2.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Breast and prostate cancer diagnostics represent a remarkable opportunity due to high precision, reduced invasiveness, and government policies. Effectively developing breast and prostate cancer diagnostics requires a comprehensive harnessing of expertise in diagnostic technologies.
In cancer diagnosis, groundbreaking technologies and innovations such as telehealth, artificial intelligence, CRISPR, cryo-electron microscopy, the Infinium Assay, and robotic surgery are instrumental in advancing and revolutionizing the diagnostic process. The rising popularity of these technologies is expected to boost revenue across Europe.
The growing prevalence of breast and prostate cancer across Europe triggers demand for cancer diagnostics. In recent years, there has been a spike in breast and prostate cancer cases in Europe. As per Globocan 2020, there were around 531086 new breast cancer cases and 473344 prostate cancer cases in Europe.
To counter the burden of cancer, early detection and treatment is necessary. As a result, people across Europe often opt for several cancer diagnostic procedures. This is expected to boost revenue in the region.
Europe breast and prostate cancer diagnostics revenue accounted for around 0.02% of Europe's cancer diagnostics sales (valued at US$ 16.7 billion) in 2022. In the forecast period, Europe's breast and prostate diagnostics revenue is set to increase at 2.2% CAGR, reaching US$ 5,030.1 million by 2033.
The increasing focus on population-based cancer screening and early detection programs in countries across Europe represents a significant opportunity for diagnostic companies specializing in cancer diagnostics and imaging technologies. These initiatives reflect a proactive approach to addressing the burden of cancer, as early detection is often a critical factor in improving patient outcomes and reducing healthcare costs associated with advanced-stage cancer treatment.
Imaging technologies are also crucial in cancer screening and early detection programs. Advanced imaging modalities, such as mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, are employed to visualize potential cancerous lesions, enabling clinicians to make timely and accurate diagnoses.
Europe's thriving landscape of clinical trials and research collaborations focused on cancer diagnostics and treatment has positioned the continent as a hub for innovation and advancement in the fight against cancer. Due to the above factors, Europe is expected to hold a prominent global revenue share.
Increasing breast and prostate cancer cases have become a serious concern across Europe. The disease not only results in loss of lives but also impacts the economic condition of countries. As a result, the government and other healthcare organizations are taking initiatives to counter this cancer burden, creating opportunities for companies.
Principal Consultant
Advancements in molecular diagnostics, particularly in Europe, are revolutionizing the landscape of cancer diagnosis and treatment. Europe has emerged as a leader in developing and applying cutting-edge molecular diagnostic technologies, such as next-generation sequencing (NGS) and liquid biopsy techniques.
The demand for NGS is expected to rise in Europe owing to its ability to identify specific genetic mutations, alterations, and variations in a patient's tumor DNA. These genetic insights would help provide critical information about the tumor's characteristics, such as its aggressiveness, susceptibility to targeted therapies, and potential resistance mechanisms.
Liquid biopsy techniques represent another remarkable advancement in molecular diagnostics. These non-invasive tests are projected to help analyze several biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific proteins in bodily fluids, including blood or urine.
Liquid biopsies are further anticipated to offer several advantages over traditional tissue biopsies, including minimal invasiveness and the ability to monitor disease progression over time. Another factor pushing their demand is the potential for early detection and treatment adjustment. The rising popularity of these cancer diagnostics tests will likely foster growth in Europe.
The growing research & technological advances are expected to create new opportunities for local and global manufacturers entering Europe. This is anticipated to boost Europe’s share in the worldwide breast and prostate cancer diagnostics business.
The high costs associated with diagnostic tests and imaging techniques for breast and prostate cancer present a significant barrier to access for several patients, particularly those in areas with limited healthcare resources. This financial burden is projected to affect individuals and strain healthcare systems, contributing to disparities in cancer care and outcomes.
One of the primary cost factors in cancer diagnostics is the price of medical equipment and technology. State-of-the-art imaging devices, such as MRI machines, CT scanners, and high-resolution ultrasound equipment, are expected to be essential for accurate cancer diagnosis and staging.
The advanced machines come with substantial price tags, making them less accessible in resource-constrained settings. Additionally, the maintenance and upgrading of such equipment require ongoing investments, further adding to the financial strain on healthcare facilities.
The need for timely and regular screenings further exacerbates the financial burden of cancer diagnostics. Early detection is crucial for improving cancer outcomes, but the need for frequent mammograms, prostate-to-specific antigen (PSA) tests, or other screening methods can strain household budgets. This is especially difficult for individuals without adequate health insurance coverage.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below table shows the estimated growth rates of the top countries. Spain, France, and Germany are set to record higher CAGRs of 3.1%, 2.4%, and 2.1%, respectively, through 2033.
Growth Outlook by Key Countries
| Countries | Value-based CAGR |
|---|---|
| United Kingdom | 1.5% |
| Germany | 2.1% |
| Spain | 3.1% |
| Italy | 1.8% |
| France | 2.4% |
The United Kingdom is expected to remain a key country across Europe regarding breast and prostate cancer diagnostics. It is projected to attain a total valuation of US$ 667.7 million by 2033.
Demand for breast and prostate cancer diagnostics in the United Kingdom will likely rise at 1.5% CAGR during the assessment period. This is attributable to the rising prevalence of prostate cancer, favorable government support, and the growing popularity of tests such as biopsies.
Prostate cancer has risen to become the third-leading cause of cancer-related fatalities in the United Kingdom, surpassing breast cancer, despite notable improvements in survival rates for both diseases. This rise in prostate cancer cases prompts people to opt for several diagnostic tests nationwide.
According to the World Cancer Research Fund, over 150 cases of prostate cancer are diagnosed in the United Kingdom every day. This is expected to create a rising demand for prostate-specific antigen (PSA) screening and other tests. It is further anticipated to present new growth prospects for breast and prostate diagnostic companies in the country.
Prostate-specific antigen (PSA) screening has shown its potential to reduce prostate cancer mortality rates significantly. This blood test is anticipated to witness high demand as it allows for timely intervention by detecting prostate cancer at an early stage. The adoption of these tests is expected to boost revenue in the country.
Recognizing the importance of early detection and improved outcomes, the government is taking proactive steps to introduce new policies and initiatives related to PSA screening. These policies aim to increase awareness about the benefits of PSA testing, encourage routine screening for at-risk populations, and ensure that healthcare providers offer this screening as part of their preventive care services.
Germany is projected to dominate the Europe breast and prostate cancer diagnostics business by 2033. It is set to experience a CAGR of 2.1% during the forecast period. By 2033, total sales in Germany are expected to reach US$ 837.2 million.
The ongoing and progressive aging of Germany's population is anticipated to drive the demand for cancer screening. According to recent studies conducted in Germany, breast cancer was diagnosed at an older age in 2022 than in 2010.
Breast cancer is also considered the most prevalent cancer among women in Germany, making it a significant public health concern that substantially impacts individuals and the healthcare system. Hence, the growing prevalence of breast cancer in older women is expected to fuel demand in the country.
As per the Europe breast and prostate cancer diagnostics industry analysis, France is expected to witness a CAGR of 2.4% during the forecast period. It is anticipated to attain a valuation of US$ 561.5 million by 2033.
Several factors are expected to drive breast and prostate cancer diagnostics demand in France and facilitate growth. These include the increasing incidence of prostate cancer, rising awareness of early cancer detection, advances in cancer diagnostics technology, and favorable reimbursement policies.
Companies operating in France are actively investing in research & development activities to promote cancer diagnostics. This has paved the way for developing more accurate and sensitive tests, including liquid biopsies. The growing popularity of these advanced and non-invasive procedures is expected to boost revenue in France.
The government in France reimburses the cost of several cancer diagnostics tests. This is projected to make them more affordable to patients, driving their demand.
The below section predicts the biopsy segment to retain its dominance during the forecast period. It is projected to thrive at 1.7% CAGR through 2033. The imaging segment is anticipated to witness a steady CAGR of 2.8% in the forecast period.
Growth Outlook by Key Test
| Test | Value-based CAGR |
|---|---|
| Tumor Biomarkers Tests | 2.5% |
| Imaging | 2.8% |
| Biopsy | 1.7% |
| Liquid Biopsy | 2.4% |
| Immunohistochemistry | 1.4% |
| In Situ Hybridization | 2.1% |
By test, the biopsy segment held a 32.2% share in Europe in 2022. The demand for biopsies across the region is projected to rise at a CAGR of 1.7% during the assessment period. It is set to total a valuation of US$ 1,532.0 million by 2033.
Biopsy has become an ideal test for early diagnosis of cancer types, such as breast and prostate cancer. Its demand is anticipated to surge among patients as it is the only way to determine if a suspicious area is cancerous.
Biopsy is gaining traction due to additional information and the available post-to-research options. The information obtained from a biopsy is expected to help in staging cancer, which is essential for determining the extent of the disease and guiding treatment decisions.
Different types of biopsies would be used to diagnose breast and prostate cancer. For instance, women diagnosed with breast cancer often opt for a core needle biopsy. On the other hand, a transrectal ultrasound (TRUS)-guided biopsy has become a commonly opted type for prostate cancer.
High effectiveness and quick & reliable results are expected to fuel the demand for biopsies across Europe during the forecast period. The usage of imaging guidance, such as MRI or ultrasound, is also making biopsies attractive options for patients.
In the table below, the report has been analyzed based on indication. Out of the two indications, the breast cancer segment is anticipated to witness a CAGR of 1.9% in the assessment period. The prostate cancer segment, on the other hand, will likely exhibit a 2.5% from 2023 to 2033.
Growth Outlook by Key Indication
| Indication | Value-based CAGR |
|---|---|
| Breast Cancer | 1.9% |
| Prostate Cancer | 2.5% |
Based on indication, the breast cancer segment is anticipated to generate a revenue of US$ 2,552.6 million by 2033, holding a prominent share of 50.7%. This is attributable to the rising prevalence of breast cancer, growing cancer awareness, and increasing need for detecting breast cancer in its early stages to initiate proper treatment approaches.
Breast cancer has benefited significantly from early detection efforts, such as mammography screening and increased awareness. Routine screening is expected to allow for the identification of breast cancer at earlier, more treatable stages.
Robust research funding, breast cancer awareness campaigns, and advocacy efforts have all contributed to the improved prognosis by promoting early diagnosis, research breakthroughs, and improved treatment options. This, in turn, is expected to boost the target segment.
The report is analyzed in the table below based on the end user. Out of the five end users, the hospital-associated labs segment is anticipated to witness a CAGR of 2.0% in the assessment period. The independent diagnostic laboratories segment, on the other hand, will likely exhibit a 2.5% from 2023 to 2033.
Growth Outlook by Key End User
| End User | Value-based CAGR |
|---|---|
| Hospital-associated Labs | 2.0% |
| Independent Diagnostic Laboratories | 2.5% |
| Diagnostic Imaging Centers | 2.3% |
| Cancer Research Institutes | 3.0% |
| Others | 1.5% |
In Europe, hospital-associated labs hold a significant presence, representing a 44.6% share of the total value in 2022. The target segment is expected to thrive at a CAGR of 2.0% throughout the forecast period. This is attributable to the rising number of hospitals and patient inclination toward cancer diagnosis at hospitals.
Hospitals typically offer a wide range of diagnostic services under one roof, including advanced imaging technologies (MRI, CT scans, and PET scans), laboratory facilities for blood tests & biopsies, and access to specialists in several medical disciplines. This comprehensive approach is anticipated to ensure patients receive a thorough evaluation and diagnosis efficiently.
Organizations and manufacturers with robust procurement capabilities are well-positioned to foster growth and expand their businesses by collaborating with buyers & suppliers. They can innovate and create products that mutually enhance revenues and profits. Employing a holistic approach, they implement multiple strategies, including agreements, acquisitions, collaborations, and expansion, to drive progress and innovation in cancer diagnostics.
Recent Developments
| Attribute | Details |
|---|---|
| Estimated Value (2023) | US$ 4,041.5 million |
| Projected Value (2033) | US$ 5,030.1 million |
| Predicted CAGR (2023 to 2033) | 2.2% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | Value (US$ million) |
| Key Regions Covered | Western Europe; Eastern Europe; and the Rest of Europe |
| Key Countries Covered | Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic |
| Key Segments Covered | Test, Indication, End User, and Region |
| Key Companies Profiled | Koninklijke Philips N.V.; F.Hoffmann to La Roche Ltd.; Abbott Laboratories, Inc.; Bio Rad Laboratories Inc.; General Electric (GE HealthCare); QIAGEN N.V.; Agilent Technologies, Inc.; Becton, Dickinson and Company; Cook Group Inc.; Danaher (Cepheid); Siemens Healthcare GmbH; Thermo Fisher Scientific Inc.; Illumina, Inc.; Hologic, Inc; Argon Medical Devices; Vortex Biosciences, Inc.; Canon Medical Systems Corporation; Merit Medical Systems |
| Report Coverage | Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives |
The total revenue in Europe is estimated to reach US$ 4,041.5 million in 2023.
Sales in Europe are projected to total US$ 5,030.1 million by 2033.
Demand in Europe is forecast to rise at 2.2% CAGR through 2033.
Sales across Europe grew at a CAGR of 1.6% between 2018 and 2022.
Continuous advancements in cancer diagnostics and rising cancer awareness are vital trends.
The top countries driving demand are the United Kingdom, Germany, France, Poland, and Italy.
Breast cancer is generally diagnosed through imaging tests and biopsies.
The United Kingdom held a revenue share of US$ 565.4 million in 2022.
In 2022, Poland had a value share of around 9.9% in Europe.
Germany is set to thrive at a CAGR of around 2.1% over the forecast period.
Koninklijke Philips N.V. and F.Hoffmann are the key players across Europe.
1. Executive Summary
1.1. Europe Industry Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Demand Analysis Overview
2.1. Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Trends
3.1. Key Trends Impacting Growth
3.2. Development/Innovation Trends
4. Value-Added Insights
4.1. Product Adoption Analysis
4.2. Disease Epidemiology
4.3. Reimbursement Landscape
4.4. Key Developments
4.5. Europe Regulatory Scenario
4.6. PESTEL Analysis
4.7. Porters Analysis
4.8. Supply Chain Analysis
4.9. Unmet needs and Opportunities
5. Background
5.1. Macro-Economic Factors
5.1.1. Europe Healthcare Expenditure
5.1.2. Life Science Spending Outlook
5.1.3. Overall Cancer Diagnostics Industry Outlook
5.2. Forecast Factors - Relevance and Impact
5.2.1. Cancer Incidence and Prevalence
5.2.2. Advancements in Diagnostic Technologies
5.2.3. Screening Programs
5.2.4. Genomic Data Sharing and Research Collaborations
5.2.5. Strategic Collaborations
5.2.6. Cancer Survivorship Programs
5.2.7. Biomarker Discovery and Validation
5.2.8. Health Technology Assessment (HTA)
5.2.9. Cancer Screening Controversies
5.3. Key Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2022 to 2033
6.1. Historical Sales Value (US$ million) Analysis, 2018 to 2022
6.2. Current and Future Value (US$ million) Projections, 2022 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Test
7.1. Introduction / Key Findings
7.2. Historical Size (US$ million) Analysis By Test, 2018 to 2022
7.3. Current and Future Size (US$ million) Analysis and Forecast By Test, 2022 to 2033
7.3.1. Tumor Biomarkers Tests
7.3.1.1. PSA Tests
7.3.1.2. CTC Tests
7.3.1.3. HER2 Tests
7.3.1.4. BRCA Tests
7.3.1.5. Others
7.3.2. Imaging
7.3.2.1. Ultrasound
7.3.2.2. Mammography
7.3.2.3. MRI Scan
7.3.2.4. PET Scan
7.3.2.5. CT Scan
7.3.2.6. SPECT and Others
7.3.3. Biopsy
7.3.3.1. Needle Biopsy
7.3.3.2. Endoscopic Biopsy
7.3.3.3. Bone Marrow Biopsy
7.3.3.4. Others
7.3.4. Liquid Biopsy
7.3.4.1. CTCs (Circulatory Tumor Cells)
7.3.4.2. ctNA (Circulating Tumor Nucleic Acid)
7.3.5. Immunohistochemistry
7.3.6. In Situ Hybridization
7.4. Attractiveness Analysis By Test
8. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Indication
8.1. Introduction / Key Findings
8.2. Historical Size (US$ million) By Indication, 2018 to 2022
8.3. Current and Future Size (US$ million) Analysis and Forecast By Indication, 2022 to 2033
8.3.1. Breast Cancer
8.3.1.1. Invasive Ductal Carcinoma
8.3.1.2. Ductal Carcinoma in Situ
8.3.1.3. invasive Lobular Carcinoma
8.3.1.4. Triple Negative Breast Cancer
8.3.1.5. Others
8.3.2. Prostate Cancer
8.3.2.1. Adenocarcinoma
8.3.2.2. Squamous Cell Carcinoma
8.3.2.3. Transitional Cell Carcinoma
8.3.2.4. Neuroendocrine Tumors
8.3.2.5. Others
8.4. Attractiveness Analysis By Indication
9. Sales Analysis 2018 to 2022 and Forecast 2022 to 2033, By End User
9.1. Introduction / Key Findings
9.2. Historical Size (US$ million) By End User, 2018 to 2022
9.3. Current and Future Size (US$ million) Analysis and Forecast By End User, 2022 to 2033
9.3.1. Hospital Associated Labs
9.3.2. Independent Diagnostic Laboratories
9.3.3. Diagnostic Imaging Centers
9.3.4. Cancer Research Institutes
9.3.5. Others
9.4. Attractiveness Analysis By End User
10. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Region
10.1. Introduction / Key Findings
10.2. Historical Size (US$ million) Trend Analysis by Region, 2018 to 2022
10.3. Current and Future Size (US$ million) Analysis and Forecast by Region, 2022 to 2033
10.3.1. Western Europe
10.3.1.1. United Kingdom
10.3.1.2. Germany
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. BENELUX
10.3.1.7. Nordics
10.3.2. Eastern Europe
10.3.2.1. Poland
10.3.2.2. Hungary
10.3.2.3. Romania
10.3.2.4. Russia
10.3.2.5. Czech Republic
10.3.3. Rest of Europe
10.4. Attractiveness Analysis by Region
11. United Kingdom Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
11.1. Introduction
11.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
11.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
11.3.1. By States
11.3.1.1. England
11.3.1.2. Wales
11.3.1.3. Northern Ireland
11.3.1.4. Scotland
11.3.2. By Test
11.3.3. By Indication
11.3.4. By End User
11.4. Attractiveness Analysis
11.4.1. By States
11.4.2. By Test
11.4.3. By Indication
11.4.4. By End User
11.5. State-Level Analysis and Forecast
11.5.1. England Demand Analysis
11.5.1.1. Introduction
11.5.1.2. Demand Analysis and Forecast by Taxonomy
11.5.1.2.1. Test
11.5.1.2.2. By Indication
11.5.1.2.3. By End User
11.5.2. Wales Demand Analysis
11.5.2.1. Introduction
11.5.2.2. Demand Analysis and Forecast by Taxonomy
11.5.2.2.1. Test
11.5.2.2.2. By Indication
11.5.2.2.3. By End User
11.5.3. Northern Ireland Demand Analysis
11.5.3.1. Introduction
11.5.3.2. Demand Analysis and Forecast by Taxonomy
11.5.3.2.1. Test
11.5.3.2.2. By Indication
11.5.3.2.3. By End User
11.5.4. Scotland Demand Analysis
11.5.4.1. Introduction
11.5.4.2. Demand Analysis and Forecast by Taxonomy
11.5.4.2.1. Test
11.5.4.2.2. By Indication
11.5.4.2.3. By End User
12. Germany Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
12.1. Introduction
12.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
12.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
12.3.1. By States
12.3.1.1. Baden-Württemberg
12.3.1.2. Bavaria
12.3.1.3. Lower Saxony
12.3.1.4. Hesse
12.3.1.5. Rest of Germany
12.3.2. By Test
12.3.3. By Indication
12.3.4. By End User
12.4. Attractiveness Analysis
12.4.1. By States
12.4.2. By Test
12.4.3. By Indication
12.4.4. By End User
12.5. States Level Analysis and Forecast
12.5.1. Baden-Württemberg Demand Analysis
12.5.1.1. Introduction
12.5.1.2. Demand Analysis and Forecast by Taxonomy
12.5.1.2.1. Test
12.5.1.2.2. By Indication
12.5.1.2.3. By End User
12.5.2. Bavaria Demand Analysis
12.5.2.1. Introduction
12.5.2.2. Demand Analysis and Forecast by Taxonomy
12.5.2.2.1. Test
12.5.2.2.2. By Indication
12.5.2.2.3. By End User
12.5.3. Argentina Demand Analysis
12.5.3.1. Introduction
12.5.3.2. Demand Analysis and Forecast by Taxonomy
12.5.3.2.1. Test
12.5.3.2.2. By Indication
12.5.3.2.3. By End User
12.5.4. Lower Saxony Demand Analysis
12.5.4.1. Introduction
12.5.4.2. Demand Analysis and Forecast by Taxonomy
12.5.4.2.1. Test
12.5.4.2.2. By Indication
12.5.4.2.3. By End User
12.5.5. Hesse Demand Analysis
12.5.5.1. Introduction
12.5.5.2. Demand Analysis and Forecast by Taxonomy
12.5.5.2.1. Test
12.5.5.2.2. By Indication
12.5.5.2.3. By End User
13. Spain Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
13.1. Introduction
13.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
13.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
13.3.1. By States
13.3.1.1. Madrid
13.3.1.2. Barcelona
13.3.1.3. Valencia
13.3.1.4. Seville
13.3.1.5. Rest of Spain
13.3.2. By Test
13.3.3. By Indication
13.3.4. By End User
13.4. Attractiveness Analysis
13.4.1. By States
13.4.2. By Test
13.4.3. By Indication
13.4.4. By End User
13.5. States Level Analysis and Forecast
13.5.1. Madrid Demand Analysis
13.5.1.1. Introduction
13.5.1.2. Demand Analysis and Forecast by Taxonomy
13.5.1.2.1. Test
13.5.1.2.2. By Indication
13.5.1.2.3. By End User
13.5.2. Barcelona Demand Analysis
13.5.2.1. Introduction
13.5.2.2. Demand Analysis and Forecast by Taxonomy
13.5.2.2.1. Test
13.5.2.2.2. By Indication
13.5.2.2.3. By End User
13.5.3. Valencia Demand Analysis
13.5.3.1. Introduction
13.5.3.2. Demand Analysis and Forecast by Taxonomy
13.5.3.2.1. Test
13.5.3.2.2. By Indication
13.5.3.2.3. By End User
13.5.4. Seville Demand Analysis
13.5.4.1. Introduction
13.5.4.2. Demand Analysis and Forecast by Taxonomy
13.5.4.2.1. Test
13.5.4.2.2. By Indication
13.5.4.2.3. By End User
14. Italy Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
14.1. Introduction
14.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
14.3.1. By States
14.3.1.1. Rome
14.3.1.2. Abruzzo
14.3.1.3. Basilicata
14.3.1.4. Calabria
14.3.1.5. Rest of Italy
14.3.2. By Test
14.3.3. By Indication
14.3.4. By End User
14.4. Attractiveness Analysis
14.4.1. By States
14.4.2. By Test
14.4.3. By Indication
14.4.4. By End User
14.5. States Level Analysis and Forecast
14.5.1. Rome Demand Analysis
14.5.1.1. Introduction
14.5.1.2. Demand Analysis and Forecast by Taxonomy
14.5.1.2.1. Test
14.5.1.2.2. By Indication
14.5.1.2.3. By End User
14.5.2. Abruzzo Demand Analysis
14.5.2.1. Introduction
14.5.2.2. Demand Analysis and Forecast by Taxonomy
14.5.2.2.1. Test
14.5.2.2.2. By Indication
14.5.2.2.3. By End User
14.5.3. Basilicata Demand Analysis
14.5.3.1. Introduction
14.5.3.2. Demand Analysis and Forecast by Taxonomy
14.5.3.2.1. Test
14.5.3.2.2. By Indication
14.5.3.2.3. By End User
14.5.4. Calabria Demand Analysis
14.5.4.1. Introduction
14.5.4.2. Demand Analysis and Forecast by Taxonomy
14.5.4.2.1. Test
14.5.4.2.2. By Indication
14.5.4.2.3. By End User
15. France Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
15.1. Introduction
15.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
15.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
15.3.1. By States
15.3.1.1. Auvergne - Rhône-Alpes
15.3.1.2. Bretagne (Brittany)
15.3.1.3. Bourgogne - Franche-Comté
15.3.1.4. Ile de France (Paris)
15.3.1.5. Rest of France
15.3.2. By Test
15.3.3. By Indication
15.3.4. By End User
15.4. Attractiveness Analysis
15.4.1. By States
15.4.2. By Test
15.4.3. By Indication
15.4.4. By End User
15.5. States Level Analysis and Forecast
15.5.1. Auvergne - Rhône-Alpes Demand Analysis
15.5.1.1. Introduction
15.5.1.2. Demand Analysis and Forecast by Taxonomy
15.5.1.2.1. Test
15.5.1.2.2. By Indication
15.5.1.2.3. By End User
15.5.2. Bretagne (Brittany) Demand Analysis
15.5.2.1. Introduction
15.5.2.2. Demand Analysis and Forecast by Taxonomy
15.5.2.2.1. Test
15.5.2.2.2. By Indication
15.5.2.2.3. By End User
15.5.3. Bourgogne - Franche-Comté Demand Analysis
15.5.3.1. Introduction
15.5.3.2. Demand Analysis and Forecast by Taxonomy
15.5.3.2.1. Test
15.5.3.2.2. By Indication
15.5.3.2.3. By End User
15.5.4. Ile de France (Paris) Demand Analysis
15.5.4.1. Introduction
15.5.4.2. Demand Analysis and Forecast by Taxonomy
15.5.4.2.1. Test
15.5.4.2.2. By Indication
15.5.4.2.3. By End User
16. BENELUX Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
16.1. Introduction
16.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
16.3.1. By Country
16.3.1.1. Belgium
16.3.1.2. Netherlands
16.3.1.3. Luxembourg
16.3.2. By Test
16.3.3. By Indication
16.3.4. By End User
16.4. Attractiveness Analysis
16.4.1. By Country
16.4.2. By Test
16.4.3. By Indication
16.4.4. By End User
16.5. Country Level Analysis and Forecast
16.5.1. Belgium Demand Analysis
16.5.1.1. Introduction
16.5.1.2. Demand Analysis and Forecast by Taxonomy
16.5.1.2.1. Test
16.5.1.2.2. By Indication
16.5.1.2.3. By End User
16.5.2. Netherland Demand Analysis
16.5.2.1. Introduction
16.5.2.2. Demand Analysis and Forecast by Taxonomy
16.5.2.2.1. Test
16.5.2.2.2. By Indication
16.5.2.2.3. By End User
16.5.3. Luxemburg Demand Analysis
16.5.3.1. Introduction
16.5.3.2. Demand Analysis and Forecast by Taxonomy
16.5.3.2.1. Test
16.5.3.2.2. By Indication
16.5.3.2.3. By End User
17. Nordics Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
17.1. Introduction
17.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
17.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
17.3.1. By Country
17.3.1.1. Denmark
17.3.1.2. Norway
17.3.1.3. Sweden
17.3.1.4. Finland
17.3.1.5. Rest of Nordics
17.3.2. By Test
17.3.3. By Indication
17.3.4. By End User
17.4. Attractiveness Analysis
17.4.1. By Country
17.4.2. By Test
17.4.3. By Indication
17.4.4. By End User
17.5. Country Level Analysis and Forecast
17.5.1. Denmark Demand Analysis
17.5.1.1. Introduction
17.5.1.2. Demand Analysis and Forecast by Taxonomy
17.5.1.2.1. Test
17.5.1.2.2. By Indication
17.5.1.2.3. By End User
17.5.2. Norway Demand Analysis
17.5.2.1. Introduction
17.5.2.2. Demand Analysis and Forecast by Taxonomy
17.5.2.2.1. Test
17.5.2.2.2. By Indication
17.5.2.2.3. By End User
17.5.3. Sweden Demand Analysis
17.5.3.1. Introduction
17.5.3.2. Demand Analysis and Forecast by Taxonomy
17.5.3.2.1. Test
17.5.3.2.2. By Indication
17.5.3.2.3. By End User
17.5.4. Finland Demand Analysis
17.5.4.1. Introduction
17.5.4.2. Demand Analysis and Forecast by Taxonomy
17.5.4.2.1. Test
17.5.4.2.2. By Indication
17.5.4.2.3. By End User
18. Poland Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
18.1. Introduction
18.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
18.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
18.3.1. By Test
18.3.2. By Indication
18.3.3. By End User
18.4. Attractiveness Analysis
18.4.1. By Test
18.4.2. By Indication
18.4.3. By End User
19. Hungary Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
19.1. Introduction
19.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
19.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
19.3.1. By Test
19.3.2. By Indication
19.3.3. By End User
19.4. Attractiveness Analysis
19.4.1. By Test
19.4.2. By Indication
19.4.3. By End User
20. Romania Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
20.1. Introduction
20.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
20.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
20.3.1. By Test
20.3.2. By Indication
20.3.3. By End User
20.4. Attractiveness Analysis
20.4.1. By Test
20.4.2. By Indication
20.4.3. By End User
21. Czech Republic Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
21.1. Introduction
21.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
21.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
21.3.1. By Test
21.3.2. By Indication
21.3.3. By End User
21.4. Attractiveness Analysis
21.4.1. By Test
21.4.2. By Indication
21.4.3. By End User
22. Russia Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
22.1. Introduction
22.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
22.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
22.3.1. By Test
22.3.2. By Indication
22.3.3. By End User
22.4. Attractiveness Analysis
22.4.1. By Test
22.4.2. By Indication
22.4.3. By End User
23. Rest of Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
23.1. Introduction
23.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
23.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
23.3.1. By Test
23.3.2. By Indication
23.3.3. By End User
23.4. Attractiveness Analysis
23.4.1. By Test
23.4.2. By Indication
23.4.3. By End User
24. Structure Analysis
24.1. Demand Analysis by Tier of Companies
24.2. Share Analysis of Top Players (%)
25. Competition Analysis
25.1. Competition Dashboard
25.2. Competition Benchmarking
25.3. Branding and Promotional Strategies
25.4. Key Development Analysis
25.5. Competition Deep Dive (Tentative List)
25.5.1. Koninklijke Philips N.V
25.5.1.1. Overview
25.5.1.2. Test Portfolio
25.5.1.3. Key Financials
25.5.1.4. SWOT Analysis
25.5.1.5. Key Developments
25.5.1.6. Sales Footprint
25.5.1.7. Strategy Overview
25.5.1.7.1. Strategy
25.5.1.7.2. Test Strategy
25.5.1.7.3. Channel Strategy
25.5.2. F.Hoffmann-La Roche Ltd.
25.5.2.1. Overview
25.5.2.2. Test Portfolio
25.5.2.3. Key Financials
25.5.2.4. SWOT Analysis
25.5.2.5. Key Developments
25.5.2.6. Sales Footprint
25.5.2.7. Strategy Overview
25.5.2.7.1. Strategy
25.5.2.7.2. Test Strategy
25.5.2.7.3. Channel Strategy
25.5.3. Abbott Laboratories, Inc.
25.5.3.1. Overview
25.5.3.2. Test Portfolio
25.5.3.3. Key Financials
25.5.3.4. SWOT Analysis
25.5.3.5. Key Developments
25.5.3.6. Sales Footprint
25.5.3.7. Strategy Overview
25.5.3.7.1. Strategy
25.5.3.7.2. Test Strategy
25.5.3.7.3. Channel Strategy
25.5.4. Bio Rad Laboratories Inc.
25.5.4.1. Overview
25.5.4.2. Test Portfolio
25.5.4.3. Key Financials
25.5.4.4. SWOT Analysis
25.5.4.5. Key Developments
25.5.4.6. Sales Footprint
25.5.4.7. Strategy Overview
25.5.4.7.1. Strategy
25.5.4.7.2. Test Strategy
25.5.4.7.3. Channel Strategy
25.5.5. General Electric (GE HealthCare)
25.5.5.1. Overview
25.5.5.2. Test Portfolio
25.5.5.3. Key Financials
25.5.5.4. SWOT Analysis
25.5.5.5. Key Developments
25.5.5.6. Sales Footprint
25.5.5.7. Strategy Overview
25.5.5.7.1. Strategy
25.5.5.7.2. Test Strategy
25.5.5.7.3. Channel Strategy
25.5.6. QIAGEN N.V.
25.5.6.1. Overview
25.5.6.2. Test Portfolio
25.5.6.3. Key Financials
25.5.6.4. SWOT Analysis
25.5.6.5. Key Developments
25.5.6.6. Sales Footprint
25.5.6.7. Strategy Overview
25.5.6.7.1. Strategy
25.5.6.7.2. Test Strategy
25.5.6.7.3. Channel Strategy
25.5.7. Agilent Technologies, Inc.
25.5.7.1. Overview
25.5.7.2. Test Portfolio
25.5.7.3. Key Financials
25.5.7.4. SWOT Analysis
25.5.7.5. Key Developments
25.5.7.6. Sales Footprint
25.5.7.7. Strategy Overview
25.5.7.7.1. Strategy
25.5.7.7.2. Test Strategy
25.5.7.7.3. Channel Strategy
25.5.8. Becton, Dickinson and Company
25.5.8.1. Overview
25.5.8.2. Test Portfolio
25.5.8.3. Key Financials
25.5.8.4. SWOT Analysis
25.5.8.5. Key Developments
25.5.8.6. Sales Footprint
25.5.8.7. Strategy Overview
25.5.8.7.1. Strategy
25.5.8.7.2. Test Strategy
25.5.8.7.3. Channel Strategy
25.5.9. Cook Group Inc.
25.5.9.1. Overview
25.5.9.2. Test Portfolio
25.5.9.3. Key Financials
25.5.9.4. SWOT Analysis
25.5.9.5. Key Developments
25.5.9.6. Sales Footprint
25.5.9.7. Strategy Overview
25.5.9.7.1. Strategy
25.5.9.7.2. Test Strategy
25.5.9.7.3. Channel Strategy
25.5.10. Danaher (Cepheid)
25.5.10.1. Overview
25.5.10.2. Test Portfolio
25.5.10.3. Key Financials
25.5.10.4. SWOT Analysis
25.5.10.5. Key Developments
25.5.10.6. Sales Footprint
25.5.10.7. Strategy Overview
25.5.10.7.1. Strategy
25.5.10.7.2. Test Strategy
25.5.10.7.3. Channel Strategy
25.5.11. Siemens Healthcare GmbH
25.5.11.1. Overview
25.5.11.2. Test Portfolio
25.5.11.3. Key Financials
25.5.11.4. SWOT Analysis
25.5.11.5. Key Developments
25.5.11.6. Sales Footprint
25.5.11.7. Strategy Overview
25.5.11.7.1. Strategy
25.5.11.7.2. Test Strategy
25.5.11.7.3. Channel Strategy
25.5.12. Thermo Fisher Scientific Inc.
25.5.12.1. Overview
25.5.12.2. Test Portfolio
25.5.12.3. Key Financials
25.5.12.4. SWOT Analysis
25.5.12.5. Key Developments
25.5.12.6. Sales Footprint
25.5.12.7. Strategy Overview
25.5.12.7.1. Strategy
25.5.12.7.2. Test Strategy
25.5.12.7.3. Channel Strategy
25.5.13. Illumina, Inc.
25.5.13.1. Overview
25.5.13.2. Test Portfolio
25.5.13.3. Key Financials
25.5.13.4. SWOT Analysis
25.5.13.5. Key Developments
25.5.13.6. Sales Footprint
25.5.13.7. Strategy Overview
25.5.13.7.1. Strategy
25.5.13.7.2. Test Strategy
25.5.13.7.3. Channel Strategy
25.5.14. Hologic, Inc
25.5.14.1. Overview
25.5.14.2. Test Portfolio
25.5.14.3. Key Financials
25.5.14.4. SWOT Analysis
25.5.14.5. Key Developments
25.5.14.6. Sales Footprint
25.5.14.7. Strategy Overview
25.5.14.7.1. Strategy
25.5.14.7.2. Test Strategy
25.5.14.7.3. Channel Strategy
25.5.15. Argon Medical Devices
25.5.15.1. Overview
25.5.15.2. Test Portfolio
25.5.15.3. Key Financials
25.5.15.4. SWOT Analysis
25.5.15.5. Key Developments
25.5.15.6. Sales Footprint
25.5.15.7. Strategy Overview
25.5.15.7.1. Strategy
25.5.15.7.2. Test Strategy
25.5.15.7.3. Channel Strategy
25.5.16. Vortex Biosciences, Inc.
25.5.16.1. Overview
25.5.16.2. Test Portfolio
25.5.16.3. Key Financials
25.5.16.4. SWOT Analysis
25.5.16.5. Key Developments
25.5.16.6. Sales Footprint
25.5.16.7. Strategy Overview
25.5.16.7.1. Strategy
25.5.16.7.2. Test Strategy
25.5.16.7.3. Channel Strategy
25.5.17. Canon Medical Systems Corporation
25.5.17.1. Overview
25.5.17.2. Test Portfolio
25.5.17.3. Key Financials
25.5.17.4. SWOT Analysis
25.5.17.5. Key Developments
25.5.17.6. Sales Footprint
25.5.17.7. Strategy Overview
25.5.17.7.1. Strategy
25.5.17.7.2. Test Strategy
25.5.17.7.3. Channel Strategy
25.5.18. Merit Medical Systems
25.5.18.1. Overview
25.5.18.2. Test Portfolio
25.5.18.3. Key Financials
25.5.18.4. SWOT Analysis
25.5.18.5. Key Developments
25.5.18.6. Sales Footprint
25.5.18.7. Strategy Overview
25.5.18.7.1. Strategy
25.5.18.7.2. Test Strategy
25.5.18.7.3. Channel Strategy
26. Assumptions and Acronyms Used
27. Research Methodology
Explore Healthcare Insights
View Reports
Breast and Prostate Cancer Diagnostics Industry Analysis in Europe
